- Conditions
- Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pyroxamide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- Cetuximab, Carboplatin, Paclitaxel, Conventional Surgery, Radiation Therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Imipramine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 71 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Leukemia
- Interventions
- aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C)
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 44
- States / cities
- Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more
- Conditions
- Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
- Interventions
- albumin-bound paclitaxel, gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Commack, New York + 3 more
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 65 Years and older
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 917
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more
- Conditions
- Leukemia
- Interventions
- microarray analysis, molecular genetic technique, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Parkinson Disease
- Interventions
- CoQ10, GPI 1485
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- 5-FU, Bevacizumab, Folinic acid, Oxaliplatin, Vanucizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 11 more
- Conditions
- Malignant Solid Tumour, Gastroesophageal Cancer
- Interventions
- Tivantinib, FOLFOX
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1989
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Interventions
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Drug
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Rochester, New York
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Peripheral Blood Stem Cell Transplantation
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- SS1(dsFv)-PE38 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Metastases, Renal Cell Carcinoma
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
- Interventions
- Lenalidomide, Obinutuzumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, cyclophosphamide, pentostatin
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Obinutuzumab, Chlorambucil
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more
- Conditions
- Multiple Myeloma
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Olaratumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Bakersfield, California • Highland, California + 17 more